FDA Authorizes a Second Artificial Pancreas System
Tandem’s FDA-approved Control IQ system is a major improvement over other loop systems and is expected to hit the market in early 2020
In a win for all people with type 1 diabetes (even those who won’t directly benefit from this closed-loop system), the FDA has approved Tandem’s new Control IQ software for release in 2020.
This new automated glycemic control algorithm is just the second hybrid closed-loop system available to patients with an FDA clearance. And it promises tighter control, easier usability, and more customization than the current 670g automated system from Medtronic.
Lilly’s Baqsimi is a needle-free, simple treatment for severe hypoglycemia – bringing long-needed innovation to use of glucagon in emergency settings.
By Jimmy McDermott
A new premixed, liquid glucagon coming in October in a prefilled syringe and in 2020 as an auto-injector. The second stable glucagon approved this year
The FDA has approved GVOKE, a glucagon injection for the treatment of dangerously low blood sugar (severe hypoglycemia) in people with diabetes who are at least two years of age. Xeris Pharmaceutical’s GVOKE is room-temperature, liquid, stable glucagon that is ready-to-use in an emergency. It will first be launched in the US in a prefilled syringe, coming to pharmacies in October 2019. An EpiPen-like auto-injector, GVOKE HypoPen, will be launched at some point in 2020.